PXS 25Alternative Names: PXS25
Latest Information Update: 19 Apr 2016
At a glance
- Originator Pharmaxis
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fibrosis
Most Recent Events
- 01 Jun 2012 PXS 25 is still in active development for lung fibrosis
- 15 Oct 2009 Phase-I clinical trials in Fibrosis in Australia (IV)
- 30 Oct 2004 Preclinical trials in Fibrosis in Australia (IV)